Rachel M. Webster

1.1k total citations
29 papers, 767 citations indexed

About

Rachel M. Webster is a scholar working on Economics and Econometrics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rachel M. Webster has authored 29 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 9 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rachel M. Webster's work include Economic and Financial Impacts of Cancer (8 papers), Lung Cancer Treatments and Mutations (4 papers) and Liver Disease and Transplantation (3 papers). Rachel M. Webster is often cited by papers focused on Economic and Financial Impacts of Cancer (8 papers), Lung Cancer Treatments and Mutations (4 papers) and Liver Disease and Transplantation (3 papers). Rachel M. Webster collaborates with scholars based in United States, United Kingdom and Egypt. Rachel M. Webster's co-authors include Sorcha Cassidy, Sara Upponi, Roland Matthews, Nicholas M. Brown, Jean O’Connor, Joanne Morris, Gwilym J. Webb, Michael Allison, Corrina Fear and Anna Paterson and has published in prestigious journals such as Nature Reviews Drug Discovery, Transplantation and American Journal of Transplantation.

In The Last Decade

Rachel M. Webster

27 papers receiving 757 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel M. Webster United States	13	359	330	170	133	107	29	767
Shengnan Yu China	10	503 1.4×	376 1.1×	177 1.0×	100 0.8×	156 1.5×	25	942
Zhixing Guo China	14	350 1.0×	459 1.4×	110 0.6×	66 0.5×	162 1.5×	37	1.1k
Si-Qi Qiu China	14	420 1.2×	303 0.9×	281 1.7×	121 0.9×	313 2.9×	35	966
Yanjie He China	16	317 0.9×	384 1.2×	270 1.6×	108 0.8×	90 0.8×	47	816
Luca Licata Italy	7	484 1.3×	402 1.2×	187 1.1×	125 0.9×	265 2.5×	24	932
Jesús Anampa United States	7	415 1.2×	242 0.7×	117 0.7×	92 0.7×	230 2.1×	14	746
EunGi Kim South Korea	9	205 0.6×	395 1.2×	91 0.5×	86 0.6×	218 2.0×	9	716
Qianming Bai China	20	314 0.9×	412 1.2×	86 0.5×	77 0.6×	203 1.9×	82	1.2k
М. V. Zavyalova Russia	19	578 1.6×	475 1.4×	226 1.3×	122 0.9×	322 3.0×	76	1.1k
Regula Deurloo Switzerland	5	468 1.3×	316 1.0×	153 0.9×	60 0.5×	222 2.1×	12	947

Countries citing papers authored by Rachel M. Webster

Since Specialization

Citations

This map shows the geographic impact of Rachel M. Webster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel M. Webster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel M. Webster more than expected).

Fields of papers citing papers by Rachel M. Webster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel M. Webster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel M. Webster. The network helps show where Rachel M. Webster may publish in the future.

Co-authorship network of co-authors of Rachel M. Webster

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel M. Webster. A scholar is included among the top collaborators of Rachel M. Webster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel M. Webster. Rachel M. Webster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Swift, Lisa, et al.. (2025). Normothermic regional and ex situ perfusion reduces postreperfusion syndrome in donation after circulatory death liver transplantation: A retrospective comparative study. American Journal of Transplantation. 25(6). 1296–1305. 1 indexed citations

Qureshi, Saeed A., Alan Noel, Lisa Swift, et al.. (2024). Infection and Prophylaxis During Normothermic Liver Perfusion: Audit of Incidence and Pharmacokinetics of Antimicrobial Therapy. Transplantation. 108(6). 1376–1382. 2 indexed citations

Webster, Rachel M., et al.. (2024). The colorectal cancer drug market. Nature Reviews Drug Discovery. 23(6). 414–415. 3 indexed citations

Webster, Rachel M., et al.. (2024). The breast cancer drug market. Nature Reviews Drug Discovery. 23(12). 891–892. 2 indexed citations

Martin, Jack L., Sara Upponi, Lisa Swift, et al.. (2024). Localized Liver Injury During Normothermic Ex Situ Liver Perfusion Has No Impact on Short-term Liver Transplant Outcomes. Transplantation. 108(6). 1403–1409. 1 indexed citations

Webster, Rachel M., et al.. (2022). The malignant melanoma market. Nature Reviews Drug Discovery. 21(7). 489–490. 17 indexed citations

Webster, Rachel M., et al.. (2022). The endometrial carcinoma market. Nature Reviews Drug Discovery. 21(4). 255–256. 3 indexed citations

Webster, Rachel M., et al.. (2021). The breast cancer drug market. Nature Reviews Drug Discovery. 20(5). 339–340. 33 indexed citations

Webster, Rachel M., et al.. (2021). The oncology market for antibody–drug conjugates. Nature Reviews Drug Discovery. 20(8). 583–584. 73 indexed citations

10.

Webster, Rachel M., et al.. (2018). The hepatocellular carcinoma market. Nature Reviews Drug Discovery. 18(1). 13–14. 60 indexed citations

11.

Webster, Rachel M., et al.. (2018). The market for chimeric antigen receptor T cell therapies. Nature Reviews Drug Discovery. 17(3). 161–162. 112 indexed citations

12.

Webster, Rachel M., et al.. (2018). The gastroesophageal cancer drug market. Nature Reviews Drug Discovery. 17(5). 311–312. 2 indexed citations

13.

Webster, Rachel M., et al.. (2017). The SCCHN drug market. Nature Reviews Drug Discovery. 16(4). 235–236.

14.

Webster, Rachel M., et al.. (2017). The ovarian cancer drug market. Nature Reviews Drug Discovery. 16(7). 451–452. 4 indexed citations

15.

Webster, Rachel M.. (2016). Combination therapies in oncology. Nature Reviews Drug Discovery. 15(2). 81–82. 82 indexed citations

16.

Webster, Rachel M., et al.. (2016). The bladder cancer drug market. Nature Reviews Drug Discovery. 15(9). 599–600. 5 indexed citations

17.

Gabram‐Mendola, Sheryl, Jean O’Connor, Roland Matthews, et al.. (2016). Hereditary breast and ovarian cancer: risk assessment in minority women and provider knowledge gaps. The Journal of Community and Supportive Oncology. 14(6). 261–267. 7 indexed citations

18.

Webster, Rachel M., et al.. (2016). The non-small-cell lung cancer drug market. Nature Reviews Drug Discovery. 15(4). 229–230. 46 indexed citations

19.

Webster, Rachel M.. (2014). The immune checkpoint inhibitors: where are we now?. Nature Reviews Drug Discovery. 13(12). 883–884. 114 indexed citations

20.

Webster, Rachel M., et al.. (2014). The malignant melanoma landscape. Nature Reviews Drug Discovery. 13(7). 491–492. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact